Is the biotech boom starting to fade? The roaring ‘20s starts to look a little fatigued. Plus: Top 5 deals, IPOs, pacts of Q3
Biotech deal cash continued to gush through Q3, but a careful look at the details in aggregate suggests that the rosy tint to the biotech …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
